{"analyses":[{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.011","paramType":"Hazard Ratio (HR)","paramValue":"0.75","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.7","upperLimit":"71.0","value":"52.9"},{"comment":"Here, 'NA' refers that the upper limit of 95% confidence interval was not estimable because of small number of events.","groupId":"OG001","lowerLimit":"61.9","upperLimit":"NA","value":"80.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever was first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD was defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters \\[cm\\] in any axis, 50% increase in sum of product of diameters \\[SPD\\] of greater than \\[\\>\\] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 capsules of ibrutinib-matching Placebo administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a complete response (CR) or partial response (PR) continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment A up to 100.1 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment A discontinued placebo treatment.","id":"OG000","title":"Placebo + Bendamustine and Rituximab (BR) (Treatment A)"},{"description":"Participants received ibrutinib capsules 560 mg (4\\*140 mg capsule) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 mg/m\\^2 IV infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a CR or PR continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment B up to 117.2 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment B continued treatment with ibrutinib at the discretion of the investigator.","id":"OG001","title":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) analysis set included all randomized participants and classified according to the assigned treatment group, regardless of the actual treatment received. Here, N (overall number of participants analyzed) signifies number of participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 97 months","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}